Menu Search
Equities

Fresenius Medical Care AG

FMEX:GER

Fresenius Medical Care AG

Actions
Health CareHealth Care Providers
  • Price (EUR)40.34
  • Today's Change0.14 / 0.35%
  • Shares traded97.19k
  • 1 Year change-6.30%
  • Beta0.8796
Data delayed at least 15 minutes, as of May 03 2024 12:04 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 18-May-23
  • 15-Feb-24
  • 14-Mar-24
  • 18-Apr-24
  • 25-Apr-24
Select bar for recommendation details.
Recommendations25-Apr-24
Buy1
Outperform3
Hold13
Underperform3
Sell2

Share price forecast in EUR

The 21 analysts offering 12 month price targets for Fresenius Medical Care AG have a median target of 38.50, with a high estimate of 50.00 and a low estimate of 26.00. The median estimate represents a -4.23% decrease from the last price of 40.20.
High24.4%50.00
Med-4.2%38.50
Low-35.3%26.00

Dividends in EUR

In 2023, Fresenius Medical Care AG reported a dividend of 1.19 EUR, which represents a 6.25% increase over last year. The 22 analysts covering the company expect dividends of 1.13 EUR for the upcoming fiscal year, a decrease of 5.46%.
Div growth (TTM)6.25%
More ▼

Earnings history & estimates in EUR

On Feb 20, 2024, Fresenius Medical Care AG reported 4th quarter 2023 earnings of 0.88 per share.
The next earnings announcement is expected on May 07, 2024.
Average growth rate+6.28%
Fresenius Medical Care AG reported annual 2023 earnings of 2.58 per share on Feb 20, 2024.
Average growth rate-12.53%
More ▼

Revenue history & estimates in EUR

Fresenius Medical Care AG & Co. KGaA had 4th quarter 2023 revenues of 4.99bn. This bettered the 4.95bn consensus of the 6 analysts covering the company. This was 9.67% above the prior year's 4th quarter results.
Average growth rate+0.02%
Fresenius Medical Care AG & Co. KGaA had revenues for the full year 2023 of 19.45bn. This was 0.29% above the prior year's results.
Average growth rate+2.81%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.